Zhou Siwei, Hunt Kristin M, Grewal Arman S, Brothers Kimberly M, Dhaliwal Deepinder K, Shanks Robert M Q
Department of Ophthalmology, Ophthalmology Residency Program (S.Z.), University of Pittsburgh Medical Center Pittsburgh, PA; The Charles T. Campbell Ophthalmic Microbiology Laboratory (K.M.H., A.S.G., K.M.B., D.K.D, R.M.Q.S.), UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Department of Ophthalmology (OVSRC), University of Pittsburgh School of Medicine, Pittsburgh, PA; and Fox Center for Vision Restoration (K.M.B., D.K.D., R.M.Q.S.), Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh PA.
Eye Contact Lens. 2018 Nov;44 Suppl 2(Suppl 2):S143-S147. doi: 10.1097/ICL.0000000000000421.
To investigate the diffusion of moxifloxacin through bandage contact lenses (BCLs) versus corneal collagen shields (CSs), the relative ability of BCLs and CSs to release moxifloxacin, and the potential of release of moxifloxacin from CSs in the clinical setting.
Using an in vitro model, the diffusion of 5% moxifloxacin across BCLs and CSs was compared. Next, the amount of drug release from BCLs and CSs soaked in 0.5% moxifloxacin was measured. Finally, based on a clinical model, CSs were soaked in Vigamox (commercial moxifloxacin) and the total concentration released was detected. Collagen shields remained intact after 24 hr; therefore, enzymatic digestion and mechanical grinding of the CS were performed to determine whether further drug could be released. The concentration of moxifloxacin was measured using a spectrophotometer at set time points up to 24 hr.
In the diffusion assay, 35.7±10.5% diffused through the BCLs and 36.2±11.8% diffused through the CSs (P=0.77). The absorption assay demonstrated at 120 min, a total of 33.3±6.77 μg/mL was released from BCLs compared with 45.8±5.2 μg/mL from the CSs (P=0.0008). In vitro experiments to simulate clinical application of Vigamox-soaked CS found the concentration of moxifloxacin released of 127.7±7.25 μg/mL in 2 mL of phosphate-buffered saline over 24 hr.
Moxifloxacin diffuses through BCLs and CSs at similar rates; however, CSs have greater capacity to absorb and release moxifloxacin compared with BCLs. Vigamox-soaked CSs released 250 μg of moxifloxacin and may be a useful method to prevent endophthalmitis.
研究莫西沙星透过绷带式隐形眼镜（BCL）与角膜胶原盾（CS）的扩散情况、BCL和CS释放莫西沙星的相对能力，以及CS在临床环境中释放莫西沙星的潜力。
使用体外模型，比较5%莫西沙星透过BCL和CS的扩散情况。接下来，测量浸泡在0.5%莫西沙星中的BCL和CS的药物释放量。最后，基于临床模型，将CS浸泡在威克适（商用莫西沙星）中，检测释放的总浓度。24小时后胶原盾保持完整；因此，对CS进行酶消化和机械研磨，以确定是否能释放更多药物。在长达24小时的设定时间点，使用分光光度计测量莫西沙星的浓度。
在扩散试验中，35.7±10.5%透过BCL扩散，36.2±11.8%透过CS扩散（P=0.77）。吸收试验表明，在120分钟时，BCL共释放33.3±6.77μg/mL，而CS释放45.8±5.2μg/mL（P=0.0008）。模拟威克适浸泡CS临床应用的体外实验发现，在24小时内，2mL磷酸盐缓冲盐水中莫西沙星的释放浓度为127.7±7.25μg/mL。
莫西沙星透过BCL和CS的扩散速率相似；然而，与BCL相比，CS吸收和释放莫西沙星的能力更强。威克适浸泡的CS释放了250μg莫西沙星，可能是预防眼内炎的一种有用方法。
